Unaudited Financial Results for the Half Year Ended on 30th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aptus Pharma reported strong H1 FY26 results with revenue from operations of Rs. 1,437.75 lakhs, up 47.38% from Rs. 975.57 lakhs in H1 FY25. EBITDA grew 36.12% to Rs. 294.55 lakhs, though EBITDA margin compressed by 169 basis points to 20.49%. Profit After Tax (PAT) rose 33.81% to Rs. 174.69 lakhs, with PAT margin at 12.15% versus 13.38% previously. The company has fully utilized its IPO proceeds of Rs. 1,302 lakhs towards capital expenditure, working capital, and general corporate purposes. The statutory auditors issued an unqualified limited review report with no qualifications.
Strong top-line and bottom-line growth should be viewed positively by shareholders, though the slight margin compression signals rising costs. The post-IPO growth track record is encouraging, but watch for any further margin pressure in upcoming quarters.